Editas Medicine (EDIT) Revenue Growth (3y) (2018 - 2025)
Powered by 
Analysis
Editas Medicine (EDIT) Revenue Growth (3y) (2018 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 10.17% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 10.76% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 77.85% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -25.02% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 42.02% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 59.40% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 7.80% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 76.62% |
| 10 | Editas Medicine | 287.84 Mn | 141.19 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 464.20% |
| Jun 30, 2025 | -17.46% |
| Mar 31, 2025 | -11.72% |
| Dec 31, 2024 | 34.89% |
| Sep 30, 2024 | -78.57% |
| Jun 30, 2024 | 10.62% |
| Mar 31, 2024 | -44.10% |
| Dec 31, 2023 | 73.90% |
| Sep 30, 2023 | -56.05% |
| Jun 30, 2023 | -35.48% |
| Mar 31, 2023 | 19.84% |
| Dec 31, 2022 | -18.97% |
| Sep 30, 2022 | -77.82% |
| Jun 30, 2022 | 39.77% |
| Mar 31, 2022 | 48.47% |
| Dec 31, 2021 | 26.78% |
| Sep 30, 2021 | -24.71% |
| Jun 30, 2021 | -62.82% |
| Mar 31, 2021 | 18.28% |
| Dec 31, 2020 | 9.07% |